Tag: Ocugen

In a surprising market reaction, shares of biotechnology firm Ocugen experienced a significant sell-off this week, even as the company ...

Ocugen, Inc. has bolstered its balance sheet without initiating a new formal funding round. The capital infusion came via the ...

The investment thesis for biopharmaceutical company Ocugen is gaining notable support on Wall Street. In a significant endorsement, the firm ...

The biotech firm Ocugen has staged a remarkable recovery in recent months, capturing renewed attention from institutional investors. This resurgence ...

A new research report from Canaccord Genuity triggered a significant rally for Ocugen Inc. on Tuesday. The firm initiated coverage ...

The stock of biotechnology firm Ocugen has experienced a significant rally, propelled by a combination of promising clinical developments for ...

Ocugen's full-year 2025 financial results, released on March 4, 2026, underscore a period of intense clinical advancement. The company's pipeline ...

Biotechnology firm Ocugen has completed patient enrollment for the pivotal Phase 3 clinical trial of its lead candidate, OCU400, a ...

Biopharmaceutical firm Ocugen has achieved a significant clinical development goal just two days before its annual financial report. Company leadership ...

Biotechnology firm Ocugen has bolstered its financial position through a recent capital raise, providing crucial resources as it approaches significant ...